Literature DB >> 9748575

Cell death induced by topoisomerase-targeted drugs: more questions than answers.

S H Kaufmann1.   

Abstract

Chemotherapeutic agents that target topoisomerase I and II set into motion a series of biochemical changes that culminate in cell death, but only under some conditions. The realization that stabilization of covalent topoisomerase-DNA complexes is not sufficient to insure cell death has prompted investigators to examine various aspects of the drug-induced death process itself. Several discrete steps along this pathway have been identified, including (a) the processing of stabilized cleavage complexes into frank DNA strand breaks; (b) sensing of the DNA damage, leading to activation of stress-associated signaling pathways and cell cycle arrest; and (c) activation of a preexisting group of enzymes and enzyme precursors, typified by the cysteine-dependent aspartate-directed proteases (caspases), that catalyze the relatively orderly biochemical cascade of terminal events known as apoptosis. The present review discusses the evidence that these steps occur after treatment with etoposide or camptothecin, the two prototypic topoisomerase poisons that are commonly studied. As in any emerging area, a large number of questions remain to be answered about the process of cell death induced by topoisomerase-directed drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748575     DOI: 10.1016/s0167-4781(98)00136-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  67 in total

1.  Elevated extracellular [K+] inhibits death-receptor- and chemical-mediated apoptosis prior to caspase activation and cytochrome c release.

Authors:  G J Thompson; C Langlais; K Cain; E C Conley; G M Cohen
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

2.  Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis.

Authors:  P Matarrese; U Testa; R Cauda; S Vella; L Gambardella; W Malorni
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

3.  The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.

Authors:  Hai Xiao; Yong Mao; Shyamal D Desai; Nai Zhou; Chun-Yuan Ting; Jaulang Hwang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

4.  Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes.

Authors:  George Hong; Kenneth N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

5.  The cytotoxic and antitumor activities of the imidazole alkaloid polycarpin from the ascidian Polycarpa aurata and its synthetic analogues.

Authors:  A M Popov; V L Novikov; O S Radchenko; G B Elyakov
Journal:  Dokl Biochem Biophys       Date:  2002 Jul-Aug       Impact factor: 0.788

6.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

7.  14-3-3 proteins block apoptosis and differentially regulate MAPK cascades.

Authors:  H Xing; S Zhang; C Weinheimer; A Kovacs; A J Muslin
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

8.  A novel method of eliminating non-neuronal proliferating cells from cultures of mouse dorsal root ganglia.

Authors:  Parker L Andersen; J Ronald Doucette; Adil J Nazarali
Journal:  Cell Mol Neurobiol       Date:  2003-04       Impact factor: 5.046

9.  Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.

Authors:  Jennifer S Dickey; Neil Osheroff
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

10.  The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Biochemistry       Date:  2006-03-07       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.